Keith Kendall
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Keith Kendall
Keith Kendall was last confirmed as CEO at Aquestive Therapeutics, Inc. (AQST) in a filing dated April 28, 2023. Keith Kendall was last confirmed as Board Member at Aquestive Therapeutics, Inc. (AQST) in a filing dated April 29, 2022. The proxy statement of Aquestive Therapeutics, Inc. reports total compensation of $2,049,198 for Keith Kendall in fiscal 2021, including a base salary of $550,000. Disclosed compensation is on record for 3 fiscal years. Keith Kendall has spoken on 9 earnings calls across 1 company, most recently for Aquestive Therapeutics, Inc. on May 4, 2022.
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Start not stated–2023-04-28
Last confirmed by a filing; no departure on record
-
Start not stated–2022-04-29
Last confirmed by a filing; no departure on record
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2021 | Aquestive Therapeutics, Inc. (AQST) | Chief Executive Officer | $550,000 | $2,049,198 |
| 2020 | Aquestive Therapeutics, Inc. (AQST) | Chief Executive Officer | $550,000 | $1,290,418 |
| 2019 | Aquestive Therapeutics, Inc. (AQST) | Chief Executive Officer | $540,385 | $2,628,576 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.